Who is sponsoring NCT05807893?

NCT05807893 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05807893?

Interventions in NCT05807893: Serplulimab combined with bevacizumab and first-line chemotherapy.

What condition does NCT05807893 study?

NCT05807893 studies Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases.

Is NCT05807893 still recruiting?

NCT05807893 is currently completed. Last updated 13 November 2024.

Last reviewed 2024-11-13 · How we verify

NCT05807893: SUPER BRAIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

Completed Phase 2, PHASE3 Last updated 13 November 2024

What this trial tests

Phase 2, PHASE3 trial testing Serplulimab combined with bevacizumab and first-line chemotherapy in Non-small Cell Lung Cancer Stage II in 40 participants. Completed in 15 May 2024.

Timeline

14 May 2023

Primary endpoint
22 March 2024

15 May 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	14 May 2023
Primary completion	22 March 2024
Estimated completion	15 May 2024
Sites	1 location across China

Drugs / interventions tested

Serplulimab combined with bevacizumab and first-line chemotherapy — full drug profile →

Conditions studied

Non-small Cell Lung Cancer Stage II — all drugs for Non-small Cell Lung Cancer Stage II →
Bevacizumab — all drugs for Bevacizumab →
Immunotherapy — all drugs for Immunotherapy →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Non-small Cell Lung Cancer Stage II or Bevacizumab. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer.
Wen J, Yu JZ, Liu C, Ould Ismail AAO, et al · · 2024 · cited 13× · PMID 38396722 · DOI 10.3390/ijms25042044
Brain metastases from lung cancer: recent advances and novel therapeutic opportunities.
Layng SC, Betsock A, Mansouri A, Komiya T, et al · · 2025 · cited 2× · PMID 39934444 · DOI 10.1007/s12672-025-01873-0

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer Stage II

Currently open trials in the same condition.

NCT07428044 — A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT04585477 — Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05807893 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 13 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05807893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing